2013
Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug And Alcohol Dependence 2013, 132: 378-382. PMID: 23414931, PMCID: PMC3718876, DOI: 10.1016/j.drugalcdep.2013.01.005.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentMethadone doseKaplan-Meier survival analysisDose escalation procedureMethadone initiationThirty HIVMMT clinicsEvaluable participantsMaintenance treatmentOpioid dependenceMMT programSide effectsHigh dosesSurvival analysisHIVFirst weekPilot studyDoseMonthsTreatmentEscalation procedureDosesCravingParticipantsMonths of release
2006
Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. Clinical Infectious Diseases 2006, 43: s169-s172. PMID: 17109302, DOI: 10.1086/508179.BooksMeSH KeywordsAntiretroviral Therapy, Highly ActiveBuprenorphineDelivery of Health Care, IntegratedFemaleFollow-Up StudiesHealth Services ResearchHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersPrimary Health CarePrimary PreventionRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesConceptsHuman immunodeficiency virusDrug abuseCare settingsTreatment of HIVHIV primary care settingPrimary HIV care settingsMental Health Services AdministrationHIV primary careProvision of buprenorphineActive antiretroviral therapyHIV care settingsPrimary care settingCollaborative HIV ResearchHealth Services AdministrationAddiction/dependenceAntiretroviral therapyHIV infectionImmunodeficiency syndromeImmunodeficiency virusPrimary careSuccessful treatmentDrug abusersHIV researchDisease controlSubstance abuseThe Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individuals